Publications

    TR&D 1

    Peer-Reviewed Publications

    1. Parkins KM, Krishnamachary B, Jacob D, Kakkad S, Solaiyappan M, Mishra A, Mironchik Y, Penet MF, McMahon MT, Knopf P, Pichler BJ, Nimmagadda N, Bhujwalla ZM. PET/MRI and Bioluminescence Imaging Identify Hypoxia as a Cause of PD-L1 Expression Heterogeneity Radiology-Imaging Cancer. 2023;in press.
    2. Penet MF, Sharma RK, Bharti S, Mori N, Artemov D, Bhujwalla ZM. Cancer insights from magnetic resonance spectroscopy of cells and excised tumors. NMR Biomed. 2023;36(4):e4724. Epub 2022/03/10. doi: 10.1002/nbm.4724. PubMed PMID: 35262263; PubMed Central PMCID: PMCPMC9458776.
    3. Mori N, Jin J, Krishnamachary B, Mironchik Y, Wildes F, Vesuna F, Barnett JD, Bhujwalla ZM. Functional roles of FAP-alpha in metabolism, migration and invasion of human cancer cells. Front Oncol. 2023;13:1068405. Epub 2023/03/21. doi: 10.3389/fonc.2023.1068405. PubMed PMID: 36937451; PubMed Central PMCID: PMCPMC10015381.
    4. Jin J, Barnett JD, Krishnamachary B, Mironchik Y, Luo CK, Kobayashi H, Bhujwalla ZM. Evaluating nearinfrared photoimmunotherapy for targeting fibroblast activation protein-alpha expressing cells in vitro and in vivo. Cancer Sci. 2023;114(1):236-46. Epub 2022/09/29. doi: 10.1111/cas.15601. PubMed PMID: 36169301; PubMed Central PMCID: PMCPMC9807523.
    5. Goggins E, Mironchik Y, Kakkad S, Jacob D, Wildes F, Bhujwalla ZM, Krishnamachary B. Reprogramming of VEGF-mediated extracellular matrix changes through autocrine signaling. Cancer Biology and Therapy. 2023;24(1).
    6. Tan S, Chen Z, Mironchik Y, Mori N, Penet MF, Si G, Krishnamachary B, Bhujwalla ZM. VEGF Overexpression Significantly Increases Nanoparticle-Mediated siRNA Delivery and Target-Gene Downregulation. Pharmaceutics. 2022;14(6). Epub 2022/06/25. doi: 10.3390/pharmaceutics14061260. PubMed PMID: 35745832; PubMed Central PMCID: PMCPMC9229257.
    7. Jin J, Sivakumar I, Mironchik Y, Krishnamachary B, Wildes F, Barnett JD, Hung CF, Nimmagadda S, Kobayashi H, Bhujwalla ZM, Penet MF. PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model. Cancers (Basel). 2022;14(3). Epub 2022/02/16. doi: 10.3390/cancers14030619. PubMed PMID: 35158887; PubMed Central PMCID: PMCPMC8833482.
    8. Chen Z, Krishnamachary B, Mironchik Y, Ray Banerjee S, Pomper MG, Bhujwalla ZM. PSMA-specific degradable dextran for multiplexed immunotargeted siRNA therapeutics against prostate cancer. Nanoscale. 2022;14(38):14014-22. Epub 2022/09/13. doi: 10.1039/d2nr02200a. PubMed PMID: 36093754; PubMed Central PMCID: PMCPMC9844541.
    9. Barnett JD, Jin J, Penet MF, Kobayashi H, Bhujwalla ZM. Phototheranostics of Splenic Myeloid-Derived Suppressor Cells and Its Impact on Spleen Metabolism in Tumor-Bearing Mice. Cancers (Basel). 2022;14(15). Epub 2022/07/28. doi: 10.3390/cancers14153578. PubMed PMID: 35892836; PubMed Central PMCID: PMCPMC9332589.
    10. Pacheco-Torres J, Penet MF, Mironchik Y, Krishnamachary B, Bhujwalla ZM. The PD-L1 metabolic interactome intersects with choline metabolism and inflammation. Cancer Metab. 2021;9(1):10. Epub 2021/02/21. doi: 10.1186/s40170-021-00245-w. PubMed PMID: 33608051; PubMed Central PMCID: PMCPMC7893974.
    11. Ngen EJ, Chen Y, Azad BB, Boinapally S, Jacob D, Lisok A, Shen C, Hossain MS, Jin J, Bhujwalla ZM, Pomper MG, Banerjee SR. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors. Nanotheranostics. 2021;5(2):182-96. Epub 2021/02/11. doi: 10.7150/ntno.52361. PubMed PMID: 33564617; PubMed Central PMCID: PMCPMC7868004.
    12. Vagal A, Reeder SB, Sodickson DK, Goh V, Bhujwalla ZM, Krupinski EA. The Impact of the COVID-19 Pandemic on the Radiology Research Enterprise: Radiology Scientific Expert Panel. Radiology. 2020;296(3):E134-E40. Epub 2020/04/16. doi: 10.1148/radiol.2020201393. PubMed PMID: 32293224; PubMed Central PMCID: PMCPMC7233405.
    13. Penet MF, Kakkad S, Wildes F, Bhujwalla ZM. Water and Collagen Content Are High in Pancreatic Cancer: Implications for Quantitative Metabolic Imaging. Front Oncol. 2020;10:599204. Epub 2021/02/16. doi: 10.3389/fonc.2020.599204. PubMed PMID: 33585215; PubMed Central PMCID: PMCPMC7873637.
    14. Pacheco-Torres J, Penet MF, Krishnamachary B, Mironchik Y, Chen Z, Bhujwalla ZM. PD-L1 siRNA Theranostics With a Dextran Nanoparticle Highlights the Importance of Nanoparticle Delivery for Effective Tumor PD-L1 Downregulation. Front Oncol. 2020;10:614365. Epub 2021/03/16. doi: 10.3389/fonc.2020.614365. PubMed PMID: 33718115; PubMed Central PMCID: PMCPMC7947807.
    15. Krishnamachary B, Mironchik Y, Jacob D, Goggins E, Kakkad S, Ofori F, Dore-Savard L, Bharti SK, Wildes F, Penet MF, Black ME, Bhujwalla ZM. Hypoxia theranostics of a human prostate cancer xenograft and the resulting effects on the tumor microenvironment. Neoplasia. 2020;22(12):679-88. Epub 2020/11/04. doi: 10.1016/j.neo.2020.10.001. PubMed PMID: 33142234; PubMed Central PMCID: PMCPMC7586064.
    16. Chen Z, Krishnamachary B, Pachecho-Torres J, Penet MF, Bhujwalla ZM. Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020;12(2):e1595. Epub 2019/10/24. doi: 10.1002/wnan.1595. PubMed PMID: 31642207; PubMed Central PMCID: PMCPMC7360334.
    17. Kakkad S, Krishnamachary B, Jacob D, Pacheco-Torres J, Goggins E, Bharti SK, Penet MF, Bhujwalla ZM. Molecular and functional imaging insights into the role of hypoxia in cancer aggression. Cancer Metastasis Rev. 2019;38(1-2):51-64. Epub 2019/03/07. doi: 10.1007/s10555-019-09788-3. PubMed PMID: 30840168; PubMed Central PMCID: PMCPMC6625878.
    18. Jin J, Krishnamachary B, Barnett JD, Chatterjee S, Chang D, Mironchik Y, Wildes F, Jaffee EM, Nimmagadda S, Bhujwalla ZM. Human Cancer Cell Membrane-Coated Biomimetic Nanoparticles Reduce Fibroblast-Mediated Invasion and Metastasis and Induce T-Cells. ACS Appl Mater Interfaces. 2019;11(8):7850-61. Epub 2019/02/02. doi: 10.1021/acsami.8b22309. PubMed PMID: 30707559; PubMed Central PMCID: PMCPMC6628902.
    19. Jin J, Bhujwalla ZM. Biomimetic Nanoparticles Camouflaged in Cancer Cell Membranes and Their Applications in Cancer Theranostics. Front Oncol. 2019;9:1560. Epub 2020/02/11. doi: 10.3389/fonc.2019.01560. PubMed PMID: 32039028; PubMed Central PMCID: PMCPMC6985278.
    20. Bharti SK, Kakkad S, Danhier P, Wildes F, Penet MF, Krishnamachary B, Bhujwalla ZM. Hypoxia Patterns in Primary and Metastatic Prostate Cancer Environments. Neoplasia. 2019;21(2):239-46. Epub 2019/01/15. doi: 10.1016/j.neo.2018.12.004. PubMed PMID: 30639975; PubMed Central PMCID: PMCPMC6327878.
    21. Krishnamachary B, Danhier P, Kakkad S, Bharti SK, Bhujwalla ZM. Hypoxia-Induced Reporter Genes with Different Half-Lives. Methods Mol Biol. 2018;1790:113-25. Epub 2018/06/03. doi: 10.1007/978-1-4939-7860-1_9. PubMed PMID: 29858787; PubMed Central PMCID: PMCPMC7990048.
    22. Chen Z, Krishnamachary B, Penet MF, Bhujwalla ZM. Acid-degradable Dextran as an Image Guided siRNA Carrier for COX-2 Downregulation. Theranostics. 2018;8(1):1-12. Epub 2018/01/02. doi:10.7150/thno.21052. PubMed PMID: 29290789; PubMed Central PMCID: PMCPMC5743456.
    23. Bhujwalla ZM, Kakkad S, Chen Z, Jin J, Hapuarachchige S, Artemov D, Penet MF. Theranostics and metabolotheranostics for precision medicine in oncology. J Magn Reson. 2018;291:141-51. Epub 2018/05/01. doi: 10.1016/j.jmr.2018.03.004. PubMed PMID: 29705040; PubMed Central PMCID: PMCPMC5943142.

    Book Chapters

    1. Penet M-F and Bhujwalla ZM. High-Resolution 1H MRS Metabolomics of Biofluids in Cancer. European Biophysical Societies’ Association, 2022.
    2. Penet M-F, Kakkad S, Pacheco-Torres J, Bharti S, Krishnamachary, Bhujwalla ZM. Molecular and Functional Imaging and Theranostics of the Tumor Microenvironment. In: Molecular Imaging: Principles and Practice, 2nd Edition, Academic Press, 2021.
    TR&D 2

    Check back for publications for our new TR&D!

    TR&D 3

    Peer-Reviewed Publications

    1. Coughlin JM, Slania S, Du Y, Shinehouse LK, Brosnan MK, Azad BB, Holt DP, Fan H, Lesniak WG, Minn I, Rowe SP, Dannals RF, Horti AG, Pomper MG. First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3122-3128. doi: 10.1007/s00259-021-05231-4.
    2. Du Y, Minn I, Foss C, Lesniak WG, Hu F, Dannals RF, Pomper MG, Horti AG. PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP. EJNMMI Res. 2020 Jun 22;10(1):67. doi: 10.1186/s13550-020-00657-7.
    3. Du Y, Coughlin JM, Brosnan MK, Chen A, Shinehouse LK, Abdallah R, Lodge MA, Mathews WB, Liu C, Wu Y, Minn I, Finley P, Hall AW, Lesniak WG, Dannals RF, Horti AG, Pomper MG. First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2. Eur J Nucl Med Mol Imaging. 2023 Mar 6. doi: 10.1007/s00259-023-06170-y.
    4. Leung KH, Rowe SP, Leal JP, Ashrafinia S, Sadaghiani MS, Chung HW, Dalaie P, Tulbah R, Yin Y, VanDenBerg R, Werner RA, Pienta KJ, Gorin MA, Du Y, Pomper MG. Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET. EJNMMI Res. 2022 Dec 29;12(1):76. doi: 10.1186/s13550-022-00948-1.
    5. Coughlin JM, Du Y, Lesniak WG, Harrington CK, Brosnan MK, O'Toole R, Zandi A, Sweeney SE, Abdallah R, Wu Y, Holt DP, Hall AW, Dannals RF, Solnes L, Horti AG, Pomper MG. First-in-human use of 11C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor 1 receptor. EJNMMI Res. 2022 Sep 30;12(1):64. doi: 10.1186/s13550-022-00929-4.
    6. Levinstein MR, Ventriglia EN, Gomez JL, Budinich RC, Marton J, Henriksen G, Holt DP, Dannals RF, Pomper MG, Zarate CA Jr, Bonaventura J, Michaelides M. 6-O-(2-[18F]Fluoroethyl)-6-O-Desmethyl-Diprenorphine ([18F]FE-DPN) Preferentially Binds to Mu Opioid Receptors In Vivo. Mol Imaging Biol. 2023 Apr;25(2):384-390. doi: 10.1007/s11307-022-01767-5.
    7. Cheng B, Ahn HH, Nam H, Jiang Z, Gao FJ, Minn I, Pomper MG. A Unique Core-Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects. Pharmaceutics. 2022 Feb 7;14(2):373. doi: 10.3390/pharmaceutics14020373.
    8. Zhou X, Jiang J, Yang X, Liu T, Ding J, Nimmagadda S, Pomper MG, Zhu H, Zhao J, Yang Z, Li N. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. J Nucl Med. 2022 Apr;63(4):536-542. doi: 10.2967/jnumed.121.262045.
    9. Koshino K, Werner RA, Pomper MG, Bundschuh RA, Toriumi F, Higuchi T, Rowe SP. Narrative review of generative adversarial networks in medical and molecular imaging. Ann Transl Med. 2021 May;9(9):821. doi: 10.21037/atm-20-6325.
    10. Liu HW, Hu Y, Ren Y, Nam H, Santos JL, Ng S, Gong L, Brummet M, Carrington CA, Ullman CG, Pomper MG, Minn I, Mao HQ. Scalable Purification of Plasmid DNA Nanoparticles by Tangential Flow Filtration for Systemic Delivery. ACS Appl Mater Interfaces. 2021 Jul 7;13(26):30326-30336. doi: 10.1021/acsami.1c05750.
    11. Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, Gorin MA, Wang NY, Rowe SP. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Eur Urol. 2021 Jul;80(1):82-94. doi: 10.1016/j.eururo.2021.03.004.
    12. Vaidyanathan G, Mease RC, Minn I, Choi J, Chen Y, Shallal H, Kang CM, McDougald D, Kumar V, Pomper MG, Zalutsky MR. Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate specific membrane antigen for targeted alpha particle therapy of prostate cancer. Nucl Med Biol. 2021 Mar-Apr;94-95:67-80. doi: 10.1016/j.nucmedbio.2021.01.002.
    13. Ngen EJ, Chen Y, Azad BB, Boinapally S, Jacob D, Lisok A, Shen C, Hossain MS, Jin J, Bhujwalla ZM, Pomper MG, Banerjee SR. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors. Nanotheranostics. 2021 Jan 19;5(2):182-196. doi: 10.7150/ntno.52361.
    14. Hu F, Morris PJ, Bonaventura J, Fan H, Mathews WB, Holt DP, Lam S, Boehm M, Dannals RF, Pomper MG, Michaelides M, Horti AG. Eur J Med Chem. 2021 Mar 5;213:113047. doi: 10.1016/j.ejmech.2020.113047.
    15. Rowe, S. P., Pomper, M. G. (2021) Molecular imaging in oncology: current impact and future directions. CA Cancer J Clin caac.21713
    16. Hapuarachchige, S. Si, G., Huang, C. T., Lesniak, W. G., Mease, R., Guo, X., Gabrielson, K., Artemov, D. (2021) Dual-modality PET-SPECT image-guided pretargeting delivery in HER2(+) breast cancer models. Biomacromolecules 22, 4606-4617
    17. Kumar D, Mishra A, Lisok A, Kureshi R, Shelake S, Plyku D, Sen R, Doucet M, De Silva RA, Mease RC, Forde PM, Jaffee EM, Desai P, Ganguly S, Gabrielson E, Vaidya D, Spangler JB, Nimmagadda S. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proc Natl Acad Sci U S A. 2021 Sep14;118(37):e2107982118. PMID: 34508005
    18. Leung K. H., Rowe, S. P., Pomper, M. G., Du, Y. A three-stage, deep learning, ensemble approach for prognosis in patients with Parkinson’s disease. (2021) EJNMMI Res 11, 52
    19. Mease, R. C., Kang, C. M., Kumar, V., Banerjee, S. R., Minn, I., Brummet, M., Gabrielson, K. L., Feng, Y., Park, A., Kiess, A. P., Sgouros, G., Vaidyanathan, G., Zalutsky, M. R., Pomper, M. G. (2021) An improved 211At-labeled agent for PSMA-targeted alpha therapy. J Nucl Med jnumed.121.262098
    20. Khatri W., Chung H. W., Werner, R. A., Leal, J. P., Pienta, K. J., Lodge, M. A., Gorin, M. A., Pomper, M.G., Rowe, S. P. (2021) Effect of point-spread function reconstruction for indeterminate PSMA-RADS-3A lesions on PSMA-targeted PET imaging of men with prostate cancer. Diagnostics 11, 665
    21. Ordonez, A. A., Wintaco, L. M., Mota, F., Restrepo, A. F., Ruiz-Bedoya, C. A., Reyes, C. F., Uribe, L. G., Abhishek, S., D’Alessio, F. R., Holt, D. P., Dannals, R. F., Rowe, S. P., Castillo, V. R., Pomper, M. G., Granados, U., Jain, S. K. (2021) Imaging Enterobacterales infections in patients using pathogen-specific positron emission tomography. Sci Transl Med 13, scitranslmed.abe9805
    22. Sadaghiani, M. S., Sheikhbahaei, S., Werner, R. A., Pienta, K. J., Pomper, M. G., Solnes, L. B., Gorin, M. A., Rowe, S. P. (2021) A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol 80, 82-94
    23. Slania, S. L., Das, D., Lisok, A., Du, Y., Jiang, Z., Mease, R. C., Rowe, S. P., Nimmagadda, S., Yang, X., Pomper, M. G. (2021) Imaging of fibroblast activation protein in cancer xenografts using novel (4-quinolinoyl)-glycyl-2-cyanopyrrolidine-based small molecules. J Med Chem 64, 4059-4070
    24. Vaidyanathan, G., Kang, C. M., McDougald, D., Minn, I., Brummet, M., Pomper, M. G., and Zalutsky, M. R. (2018) Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors. Nucl Med Biol 62-63, 18-30
    25. De Silva, R., Gorin, M. A., Mease, R. C., Minn, I., Lisok, A., Plyku, D., Nimmagadda, S., Allaf, M. E., Yang, X., Sgouros, G., Rowe, S. P., Pomper, M.G. (2021) Process validation, cGMP production, dosimetry, and toxicity studies of the CAIX imaging agent [111In]In-XYIMSR-01 for phase I regulatory approval. J Labelled Comp Radiopharm 64, 243-250
    26. Ngen, E. J., Benham Azad, B., Boinapally, S., Lisok, A., Brummet, M., Jacob, D., Pomper, M. G., and Banerjee, S. R. (2019) MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy. Mol Pharm 16, 2060-2068
    27. Gomez, J. L., Bonaventura, J., Lesniak, W., Mathews, W. B., Sysa-Shah, P., Rodriguez, L. A., Ellis, R. J., Richie, C. T., Harvey, B. K., Dannals, R. F., Pomper, M. G., Bonci, A., and Michaelides, M. (2017) Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Science 357, 503-507
    28. Ray, S., Lisok, A., Minn, I, Josefsson, A., Kumar, V., Brummet, M., Boinapally, S., Brayton, C., Mease, R. C., Sgouros, G., Hobbs, R. F., Pomper, M. G. (2021) Preclinical evaluation of 213Bi-/225Ac-labeled low molecular-weight compounds for radiopharmaceutical therapy of prostate cancer. J Nucl Med 62 980-988
    29. Nimmagadda S. Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. Cancers (Basel). 2020 Oct 29;12(11):3173. PMID: 33137949
    30. Santhanam, P. Russell, J., Rooper, L. M., Ladenson, P. W., Pomper, M. G., Rowe, S. P. (2020) The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer. Med Oncol 37, 98
    31. Huang, C. T., Guo, X., Barinka, C., Lupold, S. E., Pomper, M. G., Gabrielson, K., Raman, V., Artemov, D., and Hapuarachchige, S. (2020) Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. Mol Pharm 17, 3392-3402
    32. Plavén-Sigray, P., Matheson, G. J., Coughlin, J. M., Hafizi, S., Laurikainen, H., Ottoy, J., De Picker, L., Rusjan, P., Hietala, J., Howes, O. D., Mizrahi, R., Morrens, M., Pomper, M. G., and Cervenka, S. (2021) Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control Differences. Biol Psychiatry 89, e5-e8
    33. Leung, K. H., Marashdeh, W., Wray, R., Ashrafinia, S., Pomper, M. G., Rahmim, A., and Jha, A. K. (2020) A physics-guided modular deep-learning based automated framework for tumor segmentation in PET. Phys Med Biol 65, 245032
    34. Werner, R. A., Derlin, T. Lapa, C., Sheikbahaei, S., Higuchi, T., Giesel, F. L., Behr, S., Drzezga, A., Kimura, H., Buck, A. K., Derlin, T., Bengel, F. M., Pomper, M. G., Gorin, M. A., Rowe, S. P. (2020) 18F-Labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics 10, 1-16
    35. Hapuarachchige, S., Huang, C. T., Donnelly, M. C., Barinka, C., Lupold, S. E., Pomper, M. G., and Artemov, D. (2020) Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer. Mol Pharm 17, 98-108
    36. Hu, Y., He, Z., Hao, Y., Gong, L., Pang, M., Howard, G. P., Ahn, H. H., Brummet, M., Chen, K., Liu, H. W., Ke, X., Zhu, J., Anderson, C. F., Cui, H., Ullman, C. G., Carrington, C. A., Pomper, M. G., Seo, J. H., Mittal, R., Minn, I., and Mao, H. Q. (2019) Kinetic Control in Assembly of Plasmid DNA/Polycation Complex Nanoparticles. ACS Nano 13, 10161-10178
    37. Banerjee, S. R., Kumar, V., Lisok, A., Chen, J., Minn, I., Brummet, M., Boinapally, S., Cole, M., Ngen, E., Wharram, B., Brayton, C., Hobbs, R. F., and Pomper, M. G. (2019) (177)Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. Eur J Nucl Med Mol Imaging 46, 2545-2557
    38. Peters, M. E., Rahman, S., Coughlin, J. M., Pomper, M. G., and Sair, H. I. (2020) Characterizing the Link Between Glial Activation and Changed Functional Connectivity in National Football League Players Using Multimodal Neuroimaging. J Neuropsychiatry Clin Neurosci 32, 191-195
    39. Rowe, S. P., Solnes, L. B., Yin, Y., Kitchen, G., Lodge, M. A., Karakatsanis, N. A., Rahmim, A., Pomper, M. G., and Leal, J. P. (2019) Imager-4D: New Software for Viewing Dynamic PET Scans and Extracting Radiomic Parameters from PET Data. J Digit Imaging 32, 1071-1080
    40. Paller, C. J., Piana, D., Eshleman, J. R., Riel, S., Denmeade, S. R., Isaacsson Velho, P., Rowe, S. P., Pomper, M. G., Antonarakis, E. S., Luo, J., and Eisenberger, M. A. (2019) A pilot study of prostate specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. Prostate 79, 1597-1603
    41. Werner, R. A., Thackeray, J. T., Pomper, M. G., Bengel, F. M., Gorin, M. A., Derlin, T., and Rowe, S. P. (2019) Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. J Clin Med 8
    42. Minn, I., Huss, D. J., Ahn, H. H., Chinn, T. M., Park, A., Jones, J., Brummet, M., Rowe, S. P., Sysa-Shah, P., Du, Y., Levitsky, H. I., and Pomper, M. G. (2019) Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Sci Adv 5, eaaw5096
    43. Lesniak, W. G., Mease, R. C., Chatterjee, S., Kumar, D., Lisok, A., Wharram, B., Kalagadda, V. R., Emens, L. A., Pomper, M. G., and Nimmagadda, S. (2019) Development of [(18)F]FPy-WL12 as a PDL1 Specific PET Imaging Peptide. Mol Imaging 18, 1536012119852189
    44. Song, X., Walczak, P., He, X., Yang, X., Pearl, M., Bulte, J. W. M., Pomper, M. G., McMahon, M. T., and Janowski, M. (2016) Salicylic acid analogues as chemical exchange saturation transfer MRI contrast agents for the assessment of brain perfusion territory and blood-brain barrier opening after intra-arterial infusion. J Cereb Blood Flow Metab 36, 1186-1194
    45. Werner, R. A., Bundschuh, R. A., Bundschuh, L., Lapa, C., Yin, Y., Javadi, M. S., Buck, A. K., Higuchi, T., Pienta, K. J., Pomper, M. G., Lodge, M. A., Gorin, M. A., and Rowe, S. P. (2020) Semiquantitative Parameters in PSMA-Targeted PET Imaging with [(18)F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. Mol Imaging Biol 22, 190-197
    46. Sahakyan, K., Li, X., Lodge, M. A., Werner, R. A., Bundschuh, R. A., Bundschuh, L., Kulkarni, H. R., Schuchardt, C., Baum, R. P., Pienta, K. J., Pomper, M. G., Ross, A. E., Gorin, M. A., and Rowe, S. P. (2020) Semiquantitative Parameters in PSMA-Targeted PET Imaging with [(18)F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake. Mol Imaging Biol 22, 181-189
    47. Coughlin, J. M., Horti, A. G., and Pomper, M. G. (2019) Opportunities in precision psychiatry using PET neuroimaging in psychosis. Neurobiol Dis 131, 104428
    48. Gomez, E., Tran, P. T., Pienta, K. J., Pomper, M. G., Gorin, M. A., and Rowe, S. P. (2019) Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT. Clin Nucl Med 44, e313-e314
    49. Reyes, D. K., Demehri, S., Werner, R. A., Pomper, M. G., Gorin, M. A., Rowe, S. P., and Pienta, K. J. (2019) PSMA-targeted [(18)F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. Urol Case Rep 23, 72-74
    50. Horti, A. G., Naik, R., Foss, C. A., Minn, I., Misheneva, V., Du, Y., Wang, Y., Mathews, W. B., Wu, Y., Hall, A., LaCourse, C., Ahn, H. H., Nam, H., Lesniak, W. G., Valentine, H., Pletnikova, O., Troncoso, J. C., Smith, M. D., Calabresi, P. A., Savonenko, A. V., Dannals, R. F., Pletnikov, M. V., and Pomper, M. G. (2019) PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci U S A 116, 1686-1691
    51. Coughlin, J. M., Yang, T., Rebman, A. W., Bechtold, K. T., Du, Y., Mathews, W. B., Lesniak, W. G., Mihm, E. A., Frey, S. M., Marshall, E. S., Rosenthal, H. B., Reekie, T. A., Kassiou, M., Dannals, R. F., Soloski, M. J., Aucott, J. N., and Pomper, M. G. (2018) Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [(11)C]DPA-713 PET. J Neuroinflammation 15, 346
    52. Kumar, D., Lisok, A., Dahmane, E., McCoy, M., Shelake, S., Chatterjee, S., Allaj, V., Sysa-Shah, P., Wharram, B., Lesniak, W. G., Tully, E., Gabrielson, E., Jaffee, E. M., Poirier, J. T., Rudin, C. M., Gobburu, J. V., Pomper, M. G., and Nimmagadda, S. (2019) Peptide-based PET quantifies target engagement of PD-L1 therapeutics. J Clin Invest 129, 616-630
    53. Werner, R. A., Thackeray, J. T., Pomper, M. G., Bengel, F. M., Gorin, M. A., Derlin, T., and Rowe, S. P. (2019) Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. J Clin Med 8
    54. Kumar, D., Lisok, A., Dahmane, E., McCoy, M., Shelake, S., Chatterjee, S., Allaj, V., Sysa-Shah, P., Wharram, B., Lesniak, W. G., Tully, E., Gabrielson, E., Jaffee, E. M., Poirier, J. T., Rudin, C. M., Gobburu, J. V., Pomper, M. G., and Nimmagadda, S. (2019) Peptide-based PET quantifies target engagement of PD-L1 therapeutics. J Clin Invest 129, 616-630
    55. Foss, C. A., Kulik, L., Ordonez, A. A., Jain, S. K., Michael Holers, V., Thurman, J. M., and Pomper, M. G. (2019) SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [(125)I]anti-C3d mAb. Mol Imaging Biol 21, 473-481
    56. Foss, C. A., Plyku, D., Ordonez, A. A., Sanchez-Bautista, J., Rosenthal, H. B., Minn, I., Lodge, M. A., Pomper, M. G., Sgouros, G., and Jain, S. K. (2018) Biodistribution and Radiation Dosimetry of (124)IDPA-713, a PET Radiotracer for Macrophage-Associated Inflammation. J Nucl Med 59, 1751-1756
    57. Zukotynski, K. A., Valliant, J., Benard, F., Rowe, S. P., Kim, C. K., Pomper, M. G., and Cho, S. Y. (2018) Flare on Serial Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer: First Observations. Clin Nucl Med 43, 213-216

    Book Chapters

    1. Rowe, S. P., Werner, R. A., Garg, T., Gafita, A., Voter, A. F., Sadaghiani, M. S., Markowski, M. C., Paller, C. J., Zalutsky, M. R., Solnes, L. B., Pomper, M. G. Small molecule vectors for endoradiotherapy. In: Lewis, J. S., Bodei, L., Zeglis, B. M., eds. Endoradiotherapy. New York, NY: Springer, in press
    2. Rowe SP, Pomper MG. Molecular imaging in oncology: Current impact and future directions. CA Cancer J Clin. 2022 Jul;72(4):333-352. doi: 10.3322/caac.21713.
    3. Solnes, L. B., Jacobs, A. H., Coughlin, J. M., Du, Y., Goel, R., Hammoud, D. A., Pomper, M. G. (2020) Central Nervous System Molecular Imaging. In: Ross, B. D., Gambhir, S. S., eds. Molecular Imaging Principles and Practice. Shelton, CT: People’s Medical Publishing House, in press
    4. Rowe, S. P., Sadaghiani, M. S., Werner, R. A., Higuchi, T., Derlin, T., Solnes, L. B., Pomper, M. G. (2020) Prostate Cancer Theranostics. In: Ross, B. D., Gambhir, S. S., eds. Molecular Imaging Principles and Practice. Shelton, CT: People’s Medical Publishing House, in press
    5. Nimmagadda, S., Shelake, S., Pomper, M. G. (2019) Preclinical experimentation in oncology. In: Lewis, J. S., Windhorst, A. D., Zeglis, B. M., eds. Radiopharmaceutical Chemistry. New York: Springer
    TR&D 4

    Peer-Reviewed Publications

    1. Coughlin JM, Slania S, Du Y, Shinehouse LK, Brosnan MK, Azad BB, Holt DP, Fan H, Lesniak WG, Minn I, Rowe SP, Dannals RF, Horti AG, Pomper MG. First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3122-3128. doi: 10.1007/s00259-021-05231-4.
    2. Du Y, Minn I, Foss C, Lesniak WG, Hu F, Dannals RF, Pomper MG, Horti AG. PET imaging of soluble epoxide hydrolase in non-human primate brain with [18F]FNDP. EJNMMI Res. 2020 Jun 22;10(1):67. doi: 10.1186/s13550-020-00657-7.
    3. Du Y, Coughlin JM, Brosnan MK, Chen A, Shinehouse LK, Abdallah R, Lodge MA, Mathews WB, Liu C, Wu Y, Minn I, Finley P, Hall AW, Lesniak WG, Dannals RF, Horti AG, Pomper MG. First-in-human imaging using [11C]MDTC: a radiotracer targeting the cannabinoid receptor type 2. Eur J Nucl Med Mol Imaging. 2023 Mar 6. doi: 10.1007/s00259-023-06170-y.
    4. Leung KH, Rowe SP, Leal JP, Ashrafinia S, Sadaghiani MS, Chung HW, Dalaie P, Tulbah R, Yin Y, VanDenBerg R, Werner RA, Pienta KJ, Gorin MA, Du Y, Pomper MG. Deep learning and radiomics framework for PSMA-RADS classification of prostate cancer on PSMA PET. EJNMMI Res. 2022 Dec 29;12(1):76. doi: 10.1186/s13550-022-00948-1.
    5. Coughlin JM, Du Y, Lesniak WG, Harrington CK, Brosnan MK, O'Toole R, Zandi A, Sweeney SE, Abdallah R, Wu Y, Holt DP, Hall AW, Dannals RF, Solnes L, Horti AG, Pomper MG. First-in-human use of 11C-CPPC with positron emission tomography for imaging the macrophage colony-stimulating factor 1 receptor. EJNMMI Res. 2022 Sep 30;12(1):64. doi: 10.1186/s13550-022-00929-4.
    6. Levinstein MR, Ventriglia EN, Gomez JL, Budinich RC, Marton J, Henriksen G, Holt DP, Dannals RF, Pomper MG, Zarate CA Jr, Bonaventura J, Michaelides M. 6-O-(2-[18F]Fluoroethyl)-6-O-Desmethyl-Diprenorphine ([18F]FE-DPN) Preferentially Binds to Mu Opioid Receptors In Vivo. Mol Imaging Biol. 2023 Apr;25(2):384-390. doi: 10.1007/s11307-022-01767-5.
    7. Cheng B, Ahn HH, Nam H, Jiang Z, Gao FJ, Minn I, Pomper MG. A Unique Core-Shell Structured, Glycol Chitosan-Based Nanoparticle Achieves Cancer-Selective Gene Delivery with Reduced Off-Target Effects. Pharmaceutics. 2022 Feb 7;14(2):373. doi: 10.3390/pharmaceutics14020373.
    8. Zhou X, Jiang J, Yang X, Liu T, Ding J, Nimmagadda S, Pomper MG, Zhu H, Zhao J, Yang Z, Li N. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. J Nucl Med. 2022 Apr;63(4):536-542. doi: 10.2967/jnumed.121.262045.
    9. Koshino K, Werner RA, Pomper MG, Bundschuh RA, Toriumi F, Higuchi T, Rowe SP. Narrative review of generative adversarial networks in medical and molecular imaging. Ann Transl Med. 2021 May;9(9):821. doi: 10.21037/atm-20-6325.
    10. Liu HW, Hu Y, Ren Y, Nam H, Santos JL, Ng S, Gong L, Brummet M, Carrington CA, Ullman CG, Pomper MG, Minn I, Mao HQ. Scalable Purification of Plasmid DNA Nanoparticles by Tangential Flow Filtration for Systemic Delivery. ACS Appl Mater Interfaces. 2021 Jul 7;13(26):30326-30336. doi: 10.1021/acsami.1c05750.
    11. Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, Gorin MA, Wang NY, Rowe SP. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Eur Urol. 2021 Jul;80(1):82-94. doi: 10.1016/j.eururo.2021.03.004.
    12. Vaidyanathan G, Mease RC, Minn I, Choi J, Chen Y, Shallal H, Kang CM, McDougald D, Kumar V, Pomper MG, Zalutsky MR. Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate specific membrane antigen for targeted alpha particle therapy of prostate cancer. Nucl Med Biol. 2021 Mar-Apr;94-95:67-80. doi: 10.1016/j.nucmedbio.2021.01.002.
    13. Ngen EJ, Chen Y, Azad BB, Boinapally S, Jacob D, Lisok A, Shen C, Hossain MS, Jin J, Bhujwalla ZM, Pomper MG, Banerjee SR. Prostate-specific membrane antigen (PSMA)-targeted photodynamic therapy enhances the delivery of PSMA-targeted magnetic nanoparticles to PSMA-expressing prostate tumors. Nanotheranostics. 2021 Jan 19;5(2):182-196. doi: 10.7150/ntno.52361.
    14. Hu F, Morris PJ, Bonaventura J, Fan H, Mathews WB, Holt DP, Lam S, Boehm M, Dannals RF, Pomper MG, Michaelides M, Horti AG. Eur J Med Chem. 2021 Mar 5;213:113047. doi: 10.1016/j.ejmech.2020.113047.
    15. Rowe, S. P., Pomper, M. G. (2021) Molecular imaging in oncology: current impact and future directions. CA Cancer J Clin caac.21713
    16. Hapuarachchige, S. Si, G., Huang, C. T., Lesniak, W. G., Mease, R., Guo, X., Gabrielson, K., Artemov, D. (2021) Dual-modality PET-SPECT image-guided pretargeting delivery in HER2(+) breast cancer models. Biomacromolecules 22, 4606-4617
    17. Kumar D, Mishra A, Lisok A, Kureshi R, Shelake S, Plyku D, Sen R, Doucet M, De Silva RA, Mease RC, Forde PM, Jaffee EM, Desai P, Ganguly S, Gabrielson E, Vaidya D, Spangler JB, Nimmagadda S. Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proc Natl Acad Sci U S A. 2021 Sep14;118(37):e2107982118. PMID: 34508005
    18. Leung K. H., Rowe, S. P., Pomper, M. G., Du, Y. A three-stage, deep learning, ensemble approach for prognosis in patients with Parkinson’s disease. (2021) EJNMMI Res 11, 52
    19. Mease, R. C., Kang, C. M., Kumar, V., Banerjee, S. R., Minn, I., Brummet, M., Gabrielson, K. L., Feng, Y., Park, A., Kiess, A. P., Sgouros, G., Vaidyanathan, G., Zalutsky, M. R., Pomper, M. G. (2021) An improved 211At-labeled agent for PSMA-targeted alpha therapy. J Nucl Med jnumed.121.262098
    20. Khatri W., Chung H. W., Werner, R. A., Leal, J. P., Pienta, K. J., Lodge, M. A., Gorin, M. A., Pomper, M.G., Rowe, S. P. (2021) Effect of point-spread function reconstruction for indeterminate PSMA-RADS-3A lesions on PSMA-targeted PET imaging of men with prostate cancer. Diagnostics 11, 665
    21. Ordonez, A. A., Wintaco, L. M., Mota, F., Restrepo, A. F., Ruiz-Bedoya, C. A., Reyes, C. F., Uribe, L. G., Abhishek, S., D’Alessio, F. R., Holt, D. P., Dannals, R. F., Rowe, S. P., Castillo, V. R., Pomper, M. G., Granados, U., Jain, S. K. (2021) Imaging Enterobacterales infections in patients using pathogen-specific positron emission tomography. Sci Transl Med 13, scitranslmed.abe9805
    22. Sadaghiani, M. S., Sheikhbahaei, S., Werner, R. A., Pienta, K. J., Pomper, M. G., Solnes, L. B., Gorin, M. A., Rowe, S. P. (2021) A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol 80, 82-94
    23. Slania, S. L., Das, D., Lisok, A., Du, Y., Jiang, Z., Mease, R. C., Rowe, S. P., Nimmagadda, S., Yang, X., Pomper, M. G. (2021) Imaging of fibroblast activation protein in cancer xenografts using novel (4-quinolinoyl)-glycyl-2-cyanopyrrolidine-based small molecules. J Med Chem 64, 4059-4070
    24. Vaidyanathan, G., Kang, C. M., McDougald, D., Minn, I., Brummet, M., Pomper, M. G., and Zalutsky, M. R. (2018) Brush border enzyme-cleavable linkers: Evaluation for reducing renal uptake of radiolabeled prostate-specific membrane antigen inhibitors. Nucl Med Biol 62-63, 18-30
    25. De Silva, R., Gorin, M. A., Mease, R. C., Minn, I., Lisok, A., Plyku, D., Nimmagadda, S., Allaf, M. E., Yang, X., Sgouros, G., Rowe, S. P., Pomper, M.G. (2021) Process validation, cGMP production, dosimetry, and toxicity studies of the CAIX imaging agent [111In]In-XYIMSR-01 for phase I regulatory approval. J Labelled Comp Radiopharm 64, 243-250
    26. Ngen, E. J., Benham Azad, B., Boinapally, S., Lisok, A., Brummet, M., Jacob, D., Pomper, M. G., and Banerjee, S. R. (2019) MRI Assessment of Prostate-Specific Membrane Antigen (PSMA) Targeting by a PSMA-Targeted Magnetic Nanoparticle: Potential for Image-Guided Therapy. Mol Pharm 16, 2060-2068
    27. Gomez, J. L., Bonaventura, J., Lesniak, W., Mathews, W. B., Sysa-Shah, P., Rodriguez, L. A., Ellis, R. J., Richie, C. T., Harvey, B. K., Dannals, R. F., Pomper, M. G., Bonci, A., and Michaelides, M. (2017) Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Science 357, 503-507
    28. Ray, S., Lisok, A., Minn, I, Josefsson, A., Kumar, V., Brummet, M., Boinapally, S., Brayton, C., Mease, R. C., Sgouros, G., Hobbs, R. F., Pomper, M. G. (2021) Preclinical evaluation of 213Bi-/225Ac-labeled low molecular-weight compounds for radiopharmaceutical therapy of prostate cancer. J Nucl Med 62 980-988
    29. Nimmagadda S. Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. Cancers (Basel). 2020 Oct 29;12(11):3173. PMID: 33137949
    30. Santhanam, P. Russell, J., Rooper, L. M., Ladenson, P. W., Pomper, M. G., Rowe, S. P. (2020) The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer. Med Oncol 37, 98
    31. Huang, C. T., Guo, X., Barinka, C., Lupold, S. E., Pomper, M. G., Gabrielson, K., Raman, V., Artemov, D., and Hapuarachchige, S. (2020) Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. Mol Pharm 17, 3392-3402
    32. Plavén-Sigray, P., Matheson, G. J., Coughlin, J. M., Hafizi, S., Laurikainen, H., Ottoy, J., De Picker, L., Rusjan, P., Hietala, J., Howes, O. D., Mizrahi, R., Morrens, M., Pomper, M. G., and Cervenka, S. (2021) Meta-analysis of the Glial Marker TSPO in Psychosis Revisited: Reconciling Inconclusive Findings of Patient-Control Differences. Biol Psychiatry 89, e5-e8
    33. Leung, K. H., Marashdeh, W., Wray, R., Ashrafinia, S., Pomper, M. G., Rahmim, A., and Jha, A. K. (2020) A physics-guided modular deep-learning based automated framework for tumor segmentation in PET. Phys Med Biol 65, 245032
    34. Werner, R. A., Derlin, T. Lapa, C., Sheikbahaei, S., Higuchi, T., Giesel, F. L., Behr, S., Drzezga, A., Kimura, H., Buck, A. K., Derlin, T., Bengel, F. M., Pomper, M. G., Gorin, M. A., Rowe, S. P. (2020) 18F-Labeled, PSMA-targeted radiotracers: leveraging the advantages of radiofluorination for prostate cancer molecular imaging. Theranostics 10, 1-16
    35. Hapuarachchige, S., Huang, C. T., Donnelly, M. C., Barinka, C., Lupold, S. E., Pomper, M. G., and Artemov, D. (2020) Cellular Delivery of Bioorthogonal Pretargeting Therapeutics in PSMA-Positive Prostate Cancer. Mol Pharm 17, 98-108
    36. Hu, Y., He, Z., Hao, Y., Gong, L., Pang, M., Howard, G. P., Ahn, H. H., Brummet, M., Chen, K., Liu, H. W., Ke, X., Zhu, J., Anderson, C. F., Cui, H., Ullman, C. G., Carrington, C. A., Pomper, M. G., Seo, J. H., Mittal, R., Minn, I., and Mao, H. Q. (2019) Kinetic Control in Assembly of Plasmid DNA/Polycation Complex Nanoparticles. ACS Nano 13, 10161-10178
    37. Banerjee, S. R., Kumar, V., Lisok, A., Chen, J., Minn, I., Brummet, M., Boinapally, S., Cole, M., Ngen, E., Wharram, B., Brayton, C., Hobbs, R. F., and Pomper, M. G. (2019) (177)Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. Eur J Nucl Med Mol Imaging 46, 2545-2557
    38. Peters, M. E., Rahman, S., Coughlin, J. M., Pomper, M. G., and Sair, H. I. (2020) Characterizing the Link Between Glial Activation and Changed Functional Connectivity in National Football League Players Using Multimodal Neuroimaging. J Neuropsychiatry Clin Neurosci 32, 191-195
    39. Rowe, S. P., Solnes, L. B., Yin, Y., Kitchen, G., Lodge, M. A., Karakatsanis, N. A., Rahmim, A., Pomper, M. G., and Leal, J. P. (2019) Imager-4D: New Software for Viewing Dynamic PET Scans and Extracting Radiomic Parameters from PET Data. J Digit Imaging 32, 1071-1080
    40. Paller, C. J., Piana, D., Eshleman, J. R., Riel, S., Denmeade, S. R., Isaacsson Velho, P., Rowe, S. P., Pomper, M. G., Antonarakis, E. S., Luo, J., and Eisenberger, M. A. (2019) A pilot study of prostate specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. Prostate 79, 1597-1603
    41. Werner, R. A., Thackeray, J. T., Pomper, M. G., Bengel, F. M., Gorin, M. A., Derlin, T., and Rowe, S. P. (2019) Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. J Clin Med 8
    42. Minn, I., Huss, D. J., Ahn, H. H., Chinn, T. M., Park, A., Jones, J., Brummet, M., Rowe, S. P., Sysa-Shah, P., Du, Y., Levitsky, H. I., and Pomper, M. G. (2019) Imaging CAR T cell therapy with PSMA-targeted positron emission tomography. Sci Adv 5, eaaw5096
    43. Lesniak, W. G., Mease, R. C., Chatterjee, S., Kumar, D., Lisok, A., Wharram, B., Kalagadda, V. R., Emens, L. A., Pomper, M. G., and Nimmagadda, S. (2019) Development of [(18)F]FPy-WL12 as a PDL1 Specific PET Imaging Peptide. Mol Imaging 18, 1536012119852189
    44. Song, X., Walczak, P., He, X., Yang, X., Pearl, M., Bulte, J. W. M., Pomper, M. G., McMahon, M. T., and Janowski, M. (2016) Salicylic acid analogues as chemical exchange saturation transfer MRI contrast agents for the assessment of brain perfusion territory and blood-brain barrier opening after intra-arterial infusion. J Cereb Blood Flow Metab 36, 1186-1194
    45. Werner, R. A., Bundschuh, R. A., Bundschuh, L., Lapa, C., Yin, Y., Javadi, M. S., Buck, A. K., Higuchi, T., Pienta, K. J., Pomper, M. G., Lodge, M. A., Gorin, M. A., and Rowe, S. P. (2020) Semiquantitative Parameters in PSMA-Targeted PET Imaging with [(18)F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake. Mol Imaging Biol 22, 190-197
    46. Sahakyan, K., Li, X., Lodge, M. A., Werner, R. A., Bundschuh, R. A., Bundschuh, L., Kulkarni, H. R., Schuchardt, C., Baum, R. P., Pienta, K. J., Pomper, M. G., Ross, A. E., Gorin, M. A., and Rowe, S. P. (2020) Semiquantitative Parameters in PSMA-Targeted PET Imaging with [(18)F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake. Mol Imaging Biol 22, 181-189
    47. Coughlin, J. M., Horti, A. G., and Pomper, M. G. (2019) Opportunities in precision psychiatry using PET neuroimaging in psychosis. Neurobiol Dis 131, 104428
    48. Gomez, E., Tran, P. T., Pienta, K. J., Pomper, M. G., Gorin, M. A., and Rowe, S. P. (2019) Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT. Clin Nucl Med 44, e313-e314
    49. Reyes, D. K., Demehri, S., Werner, R. A., Pomper, M. G., Gorin, M. A., Rowe, S. P., and Pienta, K. J. (2019) PSMA-targeted [(18)F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework. Urol Case Rep 23, 72-74
    50. Horti, A. G., Naik, R., Foss, C. A., Minn, I., Misheneva, V., Du, Y., Wang, Y., Mathews, W. B., Wu, Y., Hall, A., LaCourse, C., Ahn, H. H., Nam, H., Lesniak, W. G., Valentine, H., Pletnikova, O., Troncoso, J. C., Smith, M. D., Calabresi, P. A., Savonenko, A. V., Dannals, R. F., Pletnikov, M. V., and Pomper, M. G. (2019) PET imaging of microglia by targeting macrophage colony-stimulating factor 1 receptor (CSF1R). Proc Natl Acad Sci U S A 116, 1686-1691
    51. Coughlin, J. M., Yang, T., Rebman, A. W., Bechtold, K. T., Du, Y., Mathews, W. B., Lesniak, W. G., Mihm, E. A., Frey, S. M., Marshall, E. S., Rosenthal, H. B., Reekie, T. A., Kassiou, M., Dannals, R. F., Soloski, M. J., Aucott, J. N., and Pomper, M. G. (2018) Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [(11)C]DPA-713 PET. J Neuroinflammation 15, 346
    52. Kumar, D., Lisok, A., Dahmane, E., McCoy, M., Shelake, S., Chatterjee, S., Allaj, V., Sysa-Shah, P., Wharram, B., Lesniak, W. G., Tully, E., Gabrielson, E., Jaffee, E. M., Poirier, J. T., Rudin, C. M., Gobburu, J. V., Pomper, M. G., and Nimmagadda, S. (2019) Peptide-based PET quantifies target engagement of PD-L1 therapeutics. J Clin Invest 129, 616-630
    53. Werner, R. A., Thackeray, J. T., Pomper, M. G., Bengel, F. M., Gorin, M. A., Derlin, T., and Rowe, S. P. (2019) Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. J Clin Med 8
    54. Kumar, D., Lisok, A., Dahmane, E., McCoy, M., Shelake, S., Chatterjee, S., Allaj, V., Sysa-Shah, P., Wharram, B., Lesniak, W. G., Tully, E., Gabrielson, E., Jaffee, E. M., Poirier, J. T., Rudin, C. M., Gobburu, J. V., Pomper, M. G., and Nimmagadda, S. (2019) Peptide-based PET quantifies target engagement of PD-L1 therapeutics. J Clin Invest 129, 616-630
    55. Foss, C. A., Kulik, L., Ordonez, A. A., Jain, S. K., Michael Holers, V., Thurman, J. M., and Pomper, M. G. (2019) SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [(125)I]anti-C3d mAb. Mol Imaging Biol 21, 473-481
    56. Foss, C. A., Plyku, D., Ordonez, A. A., Sanchez-Bautista, J., Rosenthal, H. B., Minn, I., Lodge, M. A., Pomper, M. G., Sgouros, G., and Jain, S. K. (2018) Biodistribution and Radiation Dosimetry of (124)IDPA-713, a PET Radiotracer for Macrophage-Associated Inflammation. J Nucl Med 59, 1751-1756
    57. Zukotynski, K. A., Valliant, J., Benard, F., Rowe, S. P., Kim, C. K., Pomper, M. G., and Cho, S. Y. (2018) Flare on Serial Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer: First Observations. Clin Nucl Med 43, 213-216

    Book Chapters

    1. Rowe, S. P., Werner, R. A., Garg, T., Gafita, A., Voter, A. F., Sadaghiani, M. S., Markowski, M. C., Paller, C. J., Zalutsky, M. R., Solnes, L. B., Pomper, M. G. Small molecule vectors for endoradiotherapy. In: Lewis, J. S., Bodei, L., Zeglis, B. M., eds. Endoradiotherapy. New York, NY: Springer, in press
    2. Rowe SP, Pomper MG. Molecular imaging in oncology: Current impact and future directions. CA Cancer J Clin. 2022 Jul;72(4):333-352. doi: 10.3322/caac.21713.
    3. Solnes, L. B., Jacobs, A. H., Coughlin, J. M., Du, Y., Goel, R., Hammoud, D. A., Pomper, M. G. (2020) Central Nervous System Molecular Imaging. In: Ross, B. D., Gambhir, S. S., eds. Molecular Imaging Principles and Practice. Shelton, CT: People’s Medical Publishing House, in press
    4. Rowe, S. P., Sadaghiani, M. S., Werner, R. A., Higuchi, T., Derlin, T., Solnes, L. B., Pomper, M. G. (2020) Prostate Cancer Theranostics. In: Ross, B. D., Gambhir, S. S., eds. Molecular Imaging Principles and Practice. Shelton, CT: People’s Medical Publishing House, in press
    5. Nimmagadda, S., Shelake, S., Pomper, M. G. (2019) Preclinical experimentation in oncology. In: Lewis, J. S., Windhorst, A. D., Zeglis, B. M., eds. Radiopharmaceutical Chemistry. New York: Springer